Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: J Immunol. 2012 Dec 28;190(3):1351–1359. doi: 10.4049/jimmunol.1200391

Figure 6. Infusion of perforin-deficient DLI enhances tumor protection by TCRTg CD8+ T cells expanded in vivo with a tumor-specific vaccine.

Figure 6

C3H.SW recipients received TCD B6 bone marrow on day +0 followed by 30 × 106 DLI from B6 (wild type, WT or B6 prf1-/-(perforin) donors on day +14. On day +28, 10 × 106 Matahari T cells were adoptively transferred and all recipients concurrently received B6 male DC vaccine. (A) alloBMT recipients were weighed twice weekly, and on day +35, (B) all recipients were challenged with 1 × 106 MB49 tumor cells in the flank and measured twice weekly, 5 mice/group, p < 0.01 on day 35, data representative from two independent experiments.

HHS Vulnerability Disclosure